Targeting senescence and inflammation in chronic destructive TNF-driven joint pathology.

Area of Science:

• Immunology
• Gerontology
• Rheumatology

Background:

• Chronic destructive arthritis is characterized by joint inflammation and cellular senescence.
• Senescent chondrocytes contribute to the pathogenesis of arthritis.
• Targeting cellular senescence is a potential therapeutic strategy for arthritis.

Purpose of the Study:

• To investigate the efficacy of combining senolytic Dasatinib with sub-therapeutic Infliximab in a mouse model of chronic destructive arthritis.
• To evaluate the impact of this combination therapy on senescent chondrocytes and the senescence-associated secretory phenotype (SASP).

Main Methods:

• Utilized the human TNF transgenic mouse model of chronic destructive arthritis.
• Assessed senescent chondrocytes (GL13+/Ki67-) using guideline algorithmic approaches.
• Quantified the expression of SASP factors in arthritic joints.

Main Results:

• Neither Dasatinib nor sub-therapeutic Infliximab monotherapy affected the number of senescent chondrocytes.
• The combination of Dasatinib and sub-therapeutic Infliximab reduced senescent chondrocytes by 50%, comparable to therapeutic Infliximab monotherapy.
• Combination therapy decreased the expression of multiple SASP factors in arthritic joints.

Conclusions:

• Combination therapy with Dasatinib and sub-therapeutic Infliximab effectively reduces senescent chondrocytes and SASP in arthritis.
• This approach may offer a more targeted and effective treatment strategy for chronic destructive arthritis.
• Further research into the inflammation-senescence interplay could optimize treatments for age-related joint pathologies.